CD44 and breast carcinoma: It has been reported that use of the surface marker CD133 can isolate a group of breast cancer stem cells that does not overlap with CD44+/CD24− cells [23], which is consistent with our data that CD44+/CD24− cells may not have the highest tumorigenic ability.